Home›Trial›NCT05701800
🔬NCT05701800Phase 1Phase 2ACTIVE NOT RECRUITING

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Study Summary

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

Conditions
Herpes Zoster
Interventions / Drugs
mRNA-1468PlaceboShingrix
View on ClinicalTrials.gov ↗
Sponsor
MRNA
Moderna Inc
mRNA Therapeutics
C53/100
Study Details
Enrollment659 participants
Primary Completion—
Lead SponsorModernaTX, Inc.
Data Retrieved2026-04-11 02:55:38.209175+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.